Sight Sciences Inc Dossier - Source-backed chat

Sight Sciences Inc

SGHTNASDAQ

SectorHealth Care

IndustryHealth Care Equipment

Beta (adjusted)1.96

Intrinsic Value $6.58median of 2 methodsbased on filings through 30 Jun 2026

Market Price $9.03Price as of 1 Oct 2026

OvervaluedIntrinsic value is 27% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $497.4M

Enterprise Value $458.5M

Shares Outstanding 54.8M diluted

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Sight Sciences is demonstrating a strong commercial turnaround in 2026, driven by double-digit top-line growth and improved operational discipline. The company's core OMNI Surgical System continues to capture share in the minimally invasive glaucoma surgery (MIGS) market, while the TearCare System is showing renewed commercial traction in the dry eye segment. Backed by a robust cash position of $85.0 million, narrowing net losses, and a favorable $55.4 million patent litigation judgment against Alcon, Sight Sciences is well-positioned to execute its growth strategy and progress toward cashflow breakeven.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets4 analysts · as of 18 Aug 2026

Low · most bearish analyst$6.00

Mean target$8.75

High · most bullish analyst$12.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$5.1515%

The bear case assumes intensified competition in the MIGS space from larger players like Glaukos and Alcon, leading to pricing pressure and lower utilization of OMNI. Furthermore, delayed insurance coverage for TearCare could stall dry eye revenue growth, while persistent cash burn and prolonged litigation appeals delay the path to cashflow breakeven.

Base CaseCentral scenario

$8.2960%

The base case reflects steady execution of the company's raised FY2026 guidance, with total revenue reaching $83.0 million to $89.0 million (representing 7% to 15% growth). OMNI maintains its strong position in the MIGS market, and TearCare scales gradually. Operating expenses remain disciplined within the guided $93.0 million to $96.0 million range, steadily narrowing the net loss.

Bull CaseUpside scenario

$11.0025%

The bull case assumes rapid commercial scaling of the TearCare system following favorable insurance coverage expansions, combined with market share gains for the OMNI system in standalone glaucoma procedures. Additionally, Alcon's patent litigation appeals are resolved quickly, resulting in a cash windfall of over $55 million plus ongoing 10% royalties, accelerating the timeline to profitability.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong top-line recovery with Q1 2026 revenue growing 13% year-over-year to $19.7 million.
Robust balance sheet with $85.0 million in cash and equivalents against $40.0 million in long-term debt.
Favorable patent litigation judgment upholding $55.4 million in damages and a 10% ongoing royalty from Alcon.
High gross margins consistently maintained at 86% overall, driven by premium pricing and favorable product mix.

Key Investment Risks

Intense competition in the MIGS market from well-capitalized competitors such as Glaukos and Alcon.
Commercial execution risk in the dry eye segment, which is highly dependent on securing favorable reimbursement coverage.
Ongoing net losses ($13.0 million in Q1 2026) and cash burn, though narrowing sequentially.

Thesis Invalidation Triggers

A reversal or significant reduction of the $55.4 million patent litigation award on appeal.
Stagnation or decline in Interventional Glaucoma ordering accounts or utilization rates.
Failure to scale the Interventional Dry Eye segment, resulting in FY2026 dry eye revenue falling below the guided $6.0 million to $8.0 million range.
An unexpected increase in quarterly cash burn that threatens the company's runway before reaching cashflow breakeven.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.